TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved for TB, PA-824 (Pa) and moxifloxacin (M), in addition to existing antibiotic pyrazinamide (Z). The STAND trial will span over 50 sites in 4 continents and is expected to shorten the treatment of MDR-TB from 2 years to 6 months. Additional benefits of the novel regimen include its low cost and relative ease compared to existing treatments and its compatibility with HIV drugs.

The Bill and Melinda Gates Foundation has pledged financial support to TB Alliance for the STAND trial as well as the United Kingdom Department for International Development (DFID), US Agency for International Development (USAID) and other organizations.

For the official TB Alliance press release click here

Additional Coverage and Links

TB Alliance Grants Fosun Pharma Rights to Develop, Market Promising TB Cure in China

New and better drugs for MDR-TB on the horizon

More News
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...